Algorae Pharmaceuticals announces successful launch of AlgoraeOS AI platform

Algorae Pharmaceuticals Limited (ASX:1AI) has successfully launched its proprietary artificial intelligence platform, AlgoraeOS. The platform has achieved a Technology Readiness Level (TRL) of 3+ and integrates four proprietary AI neural networks to predict fixed-dose combination (FDC) drug targets. The platform operates on the 'Gadi' supercomputer managed by National Computational Infrastructure ('NCI Australia').

Chairman David Hainsworth on AlgoraeOS launch

Chairman David Hainsworth stated, 'The launch of AlgoraeOS marks a significant step in our strategy to leverage AI for developing fixed-dose combination drugs. By improving existing therapies rather than investing in new molecular entities, we can enhance drug efficacy while compressing the timelines and costs. This intersection of AI and drug development represents a major commercial opportunity for our shareholders and benefits the broader community through access to improved treatments.'

Algorae Pharmaceuticals' outlook and ambitions

Algorae Pharmaceuticals has successfully launched the AlgoraeOS AI platform, achieving a TRL of 3+ and high prediction correlation in major synergy metrics. The company aims to report initial in-silico FDC drug target predictions in the coming weeks and is planning pre-clinical assessments with laboratory partners. Algorae's strategy involves leveraging AI to develop novel and effective treatments, aligning with its commitment to address unmet medical needs. The company's outlook includes iterative improvements to AlgoraeOS over the next 2.5 years, with version 2.0 development already underway. Algorae's ambitions involve generating shareholder value through high-value partnering and licensing opportunities, leveraging the economic opportunity created by big pharma's investment into combatting the 'patent cliff'.